About: A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model
Creator	Chen, Hsin-Wei Liu, Hsin-Yu Liu, Shih-Jen Chen, I-Hua Chiang, I-Ping Lin, Chen-Yuan Lin, Su-I Roffler, Steve Sher, Yuh-Pyng
source	PMC
abstract	Cancer immunotherapy is attractive for antigen-specific T cell-mediated anti-tumor therapy, especially in induction of cytotoxic T lymphocytes. In this report, we evaluated human CTL epitope-induced anti-tumor effects in human lung cancer xenograft models. The tumor associated antigen L6 (TAL6) is highly expressed in human lung cancer cell lines and tumor specimens as compared to normal lung tissues. TAL6 derived peptides strongly inhibited tumor growth, cancer metastasis and prolonged survival time in HLA-A2 transgenic mice immunized with a formulation of T-helper (Th) peptide, synthetic CpG ODN, and adjuvant Montanide ISA-51 (ISA-51). Adoptive transfer of peptide-induced CTL cells from HLA-A2 transgenic mice into human tumor xenograft SCID mice significantly inhibited tumor growth. Furthermore, combination of CTL-peptide immunotherapy and gemcitabine additively improved the therapeutic effects. This pre-clinical evaluation model provides a useful platform to develop efficient immunotherapeutic drugs to treat lung cancer and demonstrates a promising strategy with benefit of antitumor immune responses worthy of further development in clinical trials.
has issue date	2015-11-26(xsd:dateTime)
bibo:pmid	26621839
has license	cc-by
sha1sum (hex)	8e014e2133b319d93ba7e9341ffe33bab3f9e265
resource representing a document's title	A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model
has PubMed Central identifier	PMC4808025
has PubMed identifier	26621839
schema:publication	Oncotarget
resource representing a document's body	covid:8e014e2133b319d93ba7e9341ffe33bab3f9e265#body_text
is schema:about of	named entity 'ODN' named entity 'survival' named entity 'highly' named entity 'tissues' named entity 'develop' covid:arg/8e014e2133b319d93ba7e9341ffe33bab3f9e265 named entity 'xenograft' named entity 'antitumor' named entity 'immunotherapy' named entity 'peptides' named entity 'drugs' named entity 'peptide' named entity 'cancer cell lines' named entity 'transgenic mice' named entity 'tumor' named entity 'T-helper' named entity 'human tumor xenograft' named entity 'therapeutic effects' named entity 'antitumor' named entity 'tumor growth' named entity 'HLA-A2' named entity 'anti-tumor' named entity 'This' named entity 'antigens' named entity 'HLA-A2' named entity 'Taiwan' named entity 'CD8 +' named entity 'CTL' named entity 'peptides' named entity 'SCID mice' named entity 'cancer cell lines' named entity 'CpG' named entity 'peptide' named entity '0.01' named entity 'peptide' named entity 'lung cancer' named entity 'CD8 +' named entity 'Rockville, MD' named entity 'cancer cell lines' named entity 'tumors' named entity 'immunosuppressive' named entity 'secretion' named entity 'protein' named entity 'subcutaneously' named entity 'staining' named entity 'therapeutic target' named entity 'pleural effusion' named entity 'epitope' named entity 'mice' named entity 'tumors' named entity 'immunization' named entity 'HLA' named entity 'HLA-A2' named entity 'tumors' named entity 'immune responses' named entity 'HLA' named entity 'HLA-A2' named entity 'peptide' named entity 'Gross examination' named entity 'effector cells' named entity 'HLA-A2' named entity 'TLR' named entity 'tumor' named entity 'tumor growth' named entity 'NHRI' named entity 'intravenously' named entity 'mice' named entity 'SCID mice' named entity 'HLA-A2' named entity 'animal model' named entity 'cancer cell' named entity 'CTL' named entity 'human tumor xenograft' named entity 'lung cancer' named entity 'melanoma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software